Digital support for inhalation treatment for chronic respiratory diseases
VisionHealth successfully closes financing round
VisionHealth GmbH, a pioneer in digital therapeutics (DTx) to enhance inhaled treatment of chronic lung diseases, announced the successful closing of a 3 million Euro pre-series A financing led by DB Speciality Invest GmbH & Co. KG, Neu-Ulm, Germany. The investment firm is owned by the successful life science entrepreneur Dr. Dietrich Bruchmann, founder and CEO of Nuvisan Pharma Holding GmbH, a renowned and fully integrated Contract Research Organization in Neu-Ulm. Founding and growing his own company, Dr. Dietrich Bruchmann has extensive entrepreneurial experience following his previous management roles with focus on M&A and Business Development at ADCURAM, DuPont and Hoechst. He will take a seat on the non-executive Board of VisionHealth.
VisionHealth GmbH
The new funds will be used to finance a second, larger study, which will enable VisionHealth to provide even stronger scientific evidence to decision makers and physicians when evaluating their recommendation of the Kata® app, a class IIa medical device (CE, MDR). The study is designed as a randomly controlled, multi-centric trial over the period of one year with around 120 patients suffering from chronic respiratory diseases asthma or COPD. It will set the basis for market access of Kata® in Germany, further EU countries and potentially, the U.S.. At the same time VisionHealth is working on strategic partnerships to gain growth and tailor its proprietary Kata® technology platform to the specific needs of the industry.
Dr. Dietrich Bruchmann, founder and CEO of Nuvisan Pharma Holding Group, said: “I am eager to see the potential of Kata® unfold, as access for asthma and COPD patients improves. Heading a CRO active in the respiratory field, I have also been intrigued by the application of the Kata® Clinical app in clinical trials: Incorrect inhaled admission of therapeutics can be a major error factor. Supporting each patient individually via the app on how to administer an inhalator properly improves patient outcomes in everyday life and also the quality of clinical trial results, ensuring maximum benefit from therapy.”
Dr. Sabine Haeussermann, CEO and founder of VisionHealth, added: “We are excited to back up the very positive proof of concept study results with more data on the efficiency of Kata®. With over 2.400 users since the first release, a stunning 83.3 % of users told us they would like to continue using the Kata® App in the future; similar amounts of users would recommend the app to friends with respiratory diseases. It is truly rewarding to see how we can make a difference for patients and improve health outcomes. We greatly appreciate the continued support of our shareholders and of our new investor, Dr. Bruchmann from Nuvisan!”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
